Zai Lab Limited (NASDAQ:ZLAB) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lowered its position in Zai Lab Limited (NASDAQ:ZLAB) by 27.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 68,685 shares of the company’s stock after selling 25,900 shares during the period. Handelsbanken Fonder AB owned approximately 0.07% of Zai Lab worth $1,877,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Bamco Inc. NY boosted its position in Zai Lab by 4.5% in the third quarter. Bamco Inc. NY now owns 1,579,349 shares of the company’s stock valued at $38,394,000 after buying an additional 67,288 shares during the last quarter. Rock Springs Capital Management LP boosted its position in Zai Lab by 1.2% in the third quarter. Rock Springs Capital Management LP now owns 1,237,023 shares of the company’s stock valued at $30,072,000 after buying an additional 14,600 shares during the last quarter. Clearbridge Investments LLC boosted its position in Zai Lab by 1.4% in the third quarter. Clearbridge Investments LLC now owns 822,888 shares of the company’s stock valued at $20,004,000 after buying an additional 11,574 shares during the last quarter. Vivo Capital LLC boosted its position in Zai Lab by 2.0% in the third quarter. Vivo Capital LLC now owns 454,606 shares of the company’s stock valued at $11,051,000 after buying an additional 9,101 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its position in Zai Lab by 251.1% in the third quarter. Hsbc Holdings PLC now owns 327,781 shares of the company’s stock valued at $7,968,000 after buying an additional 234,431 shares during the last quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Insider Activity

In other news, insider Joshua L. Smiley sold 1,988 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the transaction, the insider now owns 28,684 shares in the company, valued at approximately $449,478.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Ying Du sold 5,787 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $16.15, for a total transaction of $93,460.05. Following the transaction, the chief executive officer now owns 1,107,972 shares in the company, valued at approximately $17,893,747.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Joshua L. Smiley sold 1,988 shares of the stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $15.67, for a total value of $31,151.96. Following the completion of the transaction, the insider now directly owns 28,684 shares of the company’s stock, valued at $449,478.28. The disclosure for this sale can be found here. Insiders have sold 12,568 shares of company stock worth $208,508 in the last quarter. Corporate insiders own 5.23% of the company’s stock.

Zai Lab Stock Performance

Zai Lab stock opened at $15.91 on Friday. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $39.50. The stock’s 50 day simple moving average is $17.45 and its two-hundred day simple moving average is $22.58.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Tuesday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.11). Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. The business had revenue of $65.83 million for the quarter, compared to analysts’ expectations of $70.41 million. As a group, equities research analysts expect that Zai Lab Limited will post -3.27 earnings per share for the current year.

Analyst Ratings Changes

ZLAB has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a research report on Friday, January 12th. Citigroup lowered their price objective on Zai Lab from $123.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $64.22.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.